Abstract: Disclosed herein are RNA methyltransferase inhibitors and methods of using and making the same. The inhibitors may be used in a method for the treatment of a subject in need of a treatment for a cancer by administering an effective amount of the RNA methyltransferase inhibitor and an effective amount of a DNA damaging agent to the subject.

Abstract: Disclosed herein are Piezo1 agonists. Also disclosed herein are methods of stimulating tissue anabolism in a subject comprising administering an effective amount of a Piezo1 agonist and methods for chemically mimicking mechanical stimulation of a cell expressing Piezo1 comprising contacting a cell expressing Piezo1 with an effective amount of a Piezo1 agonist.

Abstract: Disclosed herein are RNA methyltransferase inhibitors and methods of using the same. The inhibitors may be used in a method for the treatment of a subject in need of a treatment for a cancer by administering an effective amount of an RNA methyl-transferase inhibitor to the subject.

Abstract: A training method includes following steps. A converted image group is generated by a first generator included in the first stage generative adversarial network (GAN) according to a first input image group. A reconstructed image group is generated by a second generator included in the first stage GAN according to the converted image group. The first stage GAN is updated according the reconstructed image group and the first input image group. A sampling block is added into a first stage trained GAN to form a second stage GAN. Progressively training and growing the second stage GAN network at multiple stages according to a second input image group to a last input image group to generate a last stage trained GAN.

Abstract: Mi-2? inhibitors and methods of using the same are disclosed. The methods comprise administering an effective amount of a Mi-2? inhibitor to the subject or contacting a cancer cell or a tumor with an effective amount of a Mi-2? inhibitor.

Abstract: The invention relates to compounds of the formula (VIII) wherein the moieties R1, R2, R3, R4, and R5 are as defined in the specification, and salts thereof, as well as their use, methods of use for them, methods of their synthesis, and the like. The compounds are protein tyrosine kinase inhibitors and can be used in the treatment of various cancer diseases and cancer-associated pain.

Abstract: The invention relates to compounds of the formula (VIII) wherein the moieties R1, R2, R3, R4, and R5 are as defined in the specification, and salts thereof, as well as their use, methods of use for them, methods of their synthesis, and the like. The compounds are protein tyrosine kinase inhibitors and can be used in the treatment of various cancer diseases and cancer-associated pain.

Abstract: The present invention provides vinyl indazolyl compounds useful in the treatment of cancer.

Abstract: An on-chip antenna fabricated on a chip for wireless communication is disclosed. The on-chip antenna includes a first dielectric layer arranged on a surface of the chip of the radio frequency identification tag, a grounded shielding layer arranged on the first dielectric layer, a second dielectric layer arranged on the grounded shielding layer, and a planar antenna arranged on the second dielectric layer above the grounded shielding layer. A radio frequency identification tag with an on-chip antenna and a method of fabricating an on-chip antenna on a chip for wireless communication are also disclosed.

Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, morpholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.

Abstract: An on-chip antenna fabricated on a chip for wireless communication is disclosed. The on-chip antenna includes a first dielectric layer arranged on a surface of the chip of the radio frequency identification tag, a grounded shielding layer arranged on the first dielectric layer, a second dielectric layer arranged on the grounded shielding layer, and a planar antenna arranged on the second dielectric layer above the grounded shielding layer. A radio frequency identification tag with an on-chip antenna and a method of fabricating an on-chip antenna on a chip for wireless communication are also disclosed.

Abstract: The present invention provides vinyl indazolyl compounds useful in the treatment of cancer.

Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.

Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed to inhibitors of TGF-? of Formula I: